A case of secondary diabetes mellitus with acromegaly improved by pioglitazone.
OBJECTIVE
The acromegaly patient was diagnosed with Type 2 diabetes mellitus. His HbA1c was 10.6% and fasting blood glucose (FBG) 15.3 mmol/l. We prescribed glibenclamide (10 mg/day), but his HbA1c and FBG remained high. At this stage, treatment with short-acting insulin was instigated at a dose of 20 U/day. However, the patient's blood glucose level remained unsatisfactory. We tried using pioglitazone.


METHODS
Pioglitazone was prescribed at 30 mg/day in combination with the insulin.


RESULTS
The FBG and HbA1c value decreased to 7.2 mmol/l and 7.3%, respectively, within 2 months and insulin was discontinued. Pioglitazone alone was able to control the FBG level.


CONCLUSIONS
Pioglitazone treatment might be considered as a choice for similar cases of diabetes secondary to acromegaly.
Watanabe
A
A
Third Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan. 2315com@med.nihon-u.ac.jp
Komine
F
F
Nirei
K
K
Tamura
K
K
Nabe
K
K
Aiba
N
N
Kamoshida
S
S
Otsuka
M
M
Okubo
H
H
Kanou
M
M
Sawada
S
S
Uchiyama
T
T
Nakamura
S
S
Arakawa
Y
Y
D000172:Acromegaly / Q000150:complications*; D001786:Blood Glucose / Q000032:analysis; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000209:etiology; D004359:Drug Therapy, Combination; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D000077205:Pioglitazone; D045162:Thiazolidinediones / Q000627:therapeutic use*; D016896:Treatment Outcome
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D045162:Thiazolidinediones; D000077205:Pioglitazone